NDA 021086 · Cheplapharm
Zyprexa Zydis
Olanzapine · Oral · Atypical Antipsychotic
Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Apr 6, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
496
150 Phase 3, 32 recruiting
FAERS reports
108,793
93,787 serious, 13,437 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with...
What it is approved for
From the label in effect Oct 6, 2026.
ZYPREXA ® (olanzapine) is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As ZYPREXA IntraMuscular for the: Treatment of acute agitation associated with schizophrenia and bipolar I mania....
Mechanism: The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 26, 2013 Supplement 41 · Efficacy LetterLabel
- Mar 19, 2009 Supplement 21 · Efficacy · priority review Label
- Apr 6, 2000 Original approval · Type 3 - New Dosage Form LetterOther Important Information from FDAReview
4 products under this application
- ZYPREXA ZYDIS · OLANZAPINE 20MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
- ZYPREXA ZYDIS · OLANZAPINE 10MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
- ZYPREXA ZYDIS · OLANZAPINE 15MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
- ZYPREXA ZYDIS · OLANZAPINE 5MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Olanzapine" as an intervention, any sponsor and status, largest first.
- Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00418171 · 18,239 participants · Start Feb 2002
Drug: Ziprasidone; Olanzapine · For: Schizophrenia
Sites: San Bernardino, California; ‘Aiea, Hawaii; Schaumburg, Illinois · 5 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Treatment of Refractory Nausea and Vomiting in Patients With Breast CancerPivotal-lookingCompleted
University of Rochester NCORP Research BaseAcademic, hospital or other
NCT03367572 · 1,363 participants · Start Apr 19, 2018 · Primary completion Apr 13, 2024
Drug: Dexamethasone; Netupitant/Palonosetron Hydrochloride and 2 more · For: Breast Carcinoma
Sites: Honolulu, Hawaii; Decatur, Illinois; New Orleans, Louisiana · 18 sites in all
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00212784 · 1,225 participants · Start Sep 4, 2003 · Primary completion Mar 15, 2006
Drug: asenapine; olanzapine · For: Schizophrenia; Schizoaffective Disorder
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective7,554
- weight increased6,911
- off label use6,123
- diabetes mellitus5,418
- toxicity to various agents4,386
- drug interaction4,297
- nausea4,140
- somnolence4,027
- fatigue3,681
- overdose3,489
- anxiety3,483
- vomiting3,357
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,202 |
| 2005 | 3,180 |
| 2006 | 3,626 |
| 2007 | 3,557 |
| 2008 | 1,873 |
| 2009 | 3,627 |
| 2010 | 3,267 |
| 2011 | 3,309 |
| 2012 | 2,988 |
| 2013 | 2,576 |
| 2014 | 2,974 |
| 2015 | 8,028 |
| 2016 | 3,932 |
| 2017 | 4,830 |
| 2018 | 6,096 |
| 2019 | 6,696 |
| 2020 | 6,173 |
| 2021 | 6,278 |
| 2022 | 7,109 |
| 2023 | 6,892 |
| 2024 | 7,042 |
| 2025 | 7,220 |
| 2026 | 5,317 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zyprexa Zydis (Olanzapine)
2024 spending
$3.0M
Beneficiaries
255
1,766 claims
Per beneficiary
$11,877
$33.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,230,637 |
| 2021 | $3,792,411 |
| 2022 | $3,550,664 |
| 2023 | $3,475,505 |
| 2024 | $3,028,655 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
Sandhya L, Devi Sreenivasan N, Goenka L, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis.
Lü W, Liu F, Zhang Y, et al. · BMJ Ment Health 2024 · Systematic Review, Network Meta-Analysis
- High-dose olanzapine versus clozapine for treatment-resistant schizophrenia: A systematic review and meta-analysis.
Upadhyay B, Abdolmanafi S, Bhatnagar T, et al. · Gen Hosp Psychiatry 2025 · Comparative Study, Meta-Analysis
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.